Intercept Pharmaceuticals Inc (ICPT) 256.13 $ICPT
Earnings Results, Agreements, Study Results, FDA Approvals, and Drug Trial Results - Analyst Notes on Merck, Johnson & Johnson, GlaxoSmithKline, Novartis and Intercept
PR Newswire - Mon May 12, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Merck & Co. Inc. (NYSE: MRK), Johnson & Johnson (NYSE: JNJ), GlaxoSmithKline plc (NYSE: GSK), Novartis AG (NYSE: NVS) and Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2305-100free.
Why Tesla Motors, Dendreon, and Intercept Pharmaceuticals Tumbled Today
Dan Caplinger, The Motley Fool - Motley Fool - Thu May 08, 7:35PM CDT
The stock market nixed hopes that it would rise to unprecedented highs on Thursday, but investors still fared relatively well, with the major market benchmarks delivering mixed results after giving up much larger gains earlier in the day. Yet certain...
Diabetic Nephropathy - Pipeline Review, H1 2014: 37 Companies and 58 Drugs Profiled
M2 - Thu May 08, 3:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/x6n63h/diabetic) has announced the addition of the "Diabetic Nephropathy - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Nephropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Nephropathy and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Diabetic Nephropathy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Diabetic Nephropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved: - AbbVie Inc. - Ampio Pharmaceuticals, Inc. - Angelini Group - Astellas Pharma Inc. - Bayer AG - CCRP Therapeutics GmbH - ChemoCentryx, Inc. - Chong Kun Dang Pharmaceutical Corp. - Concert Pharmaceuticals, Inc. - Cyano Biotech GmbH - Daiichi Sankyo Company, Limited - Dongwha Pharm Co., Ltd. - Eli Lilly and Company - Emergent BioSolutions Inc. - Fibrotech Therapeutics Pty. Ltd. - GNI Group Ltd. - Galectin Therapeutics - GenKyoTex S.A. - Gentium S.p.A. - Glucox Biotech AB - IMMD Inc. - Intercept Pharmaceuticals, Inc. - Inventiva SAS - Johnson & Johnson - Mesoblast Limited - Mitsubishi Pharmaceutical Corporation - Mitsubishi Tanabe Pharma Corporation - NephroGenex, Inc. - Noxxon Pharma AG Drug Profiles: - canagliflozin - atrasentan hydrochloride - baricitinib - NOX-E-36 - IMD-1041 - CS-3150 - DW-1029M - GKT-137831 - PF-00489791 - CCX-140 - LY-2382770 - bindarit - Colchicine - probucol - PF-04634817 - Pyridoxamine Dihydrochloride - GLY-230 - corticotropin - CTP-499 - MT-3995 - finerenone - cilostazol - PHN-033 - CKD-322 - Allogeneic Mesenchymal Precursor Cells For Diabetic Nephropathy - LY-3016859 - FT-011 - ASP-8232 - pirfenidone - THR-123 For more information visit http://www.researchandmarkets.com/research/x6n63h/diabetic
Intercept Pharmaceuticals Reports First Quarter 2014 Financial Results
GlobeNewswire - Wed May 07, 3:47PM CDT
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) and nonalcoholic steatohepatitis (NASH), today reported financial results for the first quarter of 2014 and provided other general business updates. Intercept will hold a conference call and audio webcast today at 4:30 p.m. ET to review this information with conference call details provided below.
Kidney Fibrosis - Pipeline Review, H1 2014: 15 Company and 18 Drug Profiles
M2 - Wed May 07, 9:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6wq329/kidney_fibrosis) has announced the addition of the "Kidney Fibrosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Kidney Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Fibrosis and special features on late-stage and discontinued projects. This report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved: - AbbVie Inc. - Angion Biomedica Corp. - BiOrion Technologies B.V. - BioLineRx, Ltd. - CisThera Inc. - Compugen Ltd. - GNI Group Ltd. - Galectin Therapeutics - Galecto Biotech AB - Genzyme Corporation - Intercept Pharmaceuticals, Inc. - Paloma Pharmaceuticals, Inc. - ProMetic Life Sciences Inc. - Raptor Pharmaceuticals Corp. - Regulus Therapeutics Inc. Drug Profiles: - paricalcitol - F-351 - CGEN-856 - CGEN-857 - cysteamine DR - INT-767 - PBI-4050 - GR-MD-02 - Anti microRNA-21 - Galectin-3 Inhibitors - 1D-11 - CT-140 - BOT-191 - BOT-190 - SOL-1 - LJ-1888 - P-529 - ANG-3298 For more information visit http://www.researchandmarkets.com/research/6w...y_fibrosis
Intercept Reports Additional Positive OCA Data in Patients With Bile Acid Diarrhea at Digestive Disease Week
GlobeNewswire - Tue May 06, 3:24PM CDT
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept) today announced new OBADIAH trial results showing potential clinical benefits of obeticholic acid (OCA) for patients with bile acid diarrhea. OCA, Intercept's lead product candidate, is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR) in development for primary biliary cirrhosis (PBC), nonalcoholic steatohepatitis (NASH) and other liver and intestinal diseases, including bile acid diarrhea. The new OBADIAH trial results were presented today at Digestive Disease Week 2014 (DDW) in Chicago. OBADIAH is an investigator-initiated and sponsored open label Phase 2 trial conducted by Professor Julian Walters and colleagues at Imperial College, London in the United Kingdom. The trial evaluated once daily administration of 25 mg OCA for two weeks in 32 patients with diarrhea. Initial results from the OBADIAH trial in primary bile acid diarrhea were presented in 2013.
Intercept to Host First Quarter 2014 Update on May 7 and Present at Upcoming Investor Conferences
GlobeNewswire - Thu May 01, 5:05AM CDT
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver and intestinal diseases, today announced that it will report first quarter 2014 financial results after the NASDAQ Market closes on Wednesday, May 7, 2014. Intercept management will conduct a conference call and audio webcast on May 7, 2014 at 4:30 p.m. ET to discuss these results and provide an update on the company's business.
Intercept Pharmaceuticals Appoints Rachel McMinn, Ph.D. as Chief Strategy Officer
GlobeNewswire - Wed Apr 30, 3:49PM CDT
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver and intestinal diseases, today announced the appointment of Rachel McMinn, Ph.D. to the newly created position of Chief Strategy Officer.
Intercept Pharmaceuticals: What Investors Need to Watch
Brian Nichols, The Motley Fool - Motley Fool - Tue Apr 29, 5:30PM CDT
After soaring on positive clinical trial news in January, shares of Intercept Pharmaceuticals have fallen 50% from their highs. The biotech, which currently sports a market cap of $5.5 billion, jumped following positive data from its drug...
Global Diarrhea Therapeutics Pipeline Review 2014
M2 - Tue Apr 29, 8:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/63vt65/diarrhea) has announced the addition of the "Diarrhea - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Diarrhea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diarrhea and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Diarrhea - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Diarrhea and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Diarrhea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Diarrhea pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Ipsen S.A. - A. Menarini Industrie Farmaceutiche Riunite Srl - Shire Plc - Mucosis B.V. - Helsinn Healthcare S.A. - Ventria Bioscience - Ache Laboratorios Farmaceuticos S/A - Ocera Therapeutics, Inc. - GP Pharm, S.A. - Tioga Pharmaceuticals, Inc. - Intercept Pharmaceuticals, Inc. - Aegis Therapeutics, LLC - Drais Pharmaceuticals, Inc. - DesignMedix, Inc. - Chongqing Zhifei Biological Products Co., Ltd. - Rottapharm|Madaus - Sanofi Pasteur SA - Inhibikase Therapeutics, Inc. - Rebiotix Inc. For more information visit http://www.researchandmarkets.com/research/63vt65/diarrhea
Global Non-Alcoholic Steatohepatitis Therapeutics Pipeline Review 2014 - Analysis of 24 Companies & 31 Drug Profiles
M2 - Mon Apr 28, 5:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7dwrzr/nonalcoholic) has announced the addition of the "Non-Alcoholic Steatohepatitis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Non-Alcoholic Steatohepatitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Non-Alcoholic Steatohepatitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Non-Alcoholic Steatohepatitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Non-Alcoholic Steatohepatitis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Isis Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Novo Nordisk A/S - Mochida Pharmaceutical Co., Ltd. - Kissei Pharmaceutical Co., Ltd. - Genfit SA - Orchid Chemicals & Pharmaceuticals Ltd - La Jolla Pharmaceutical Company - ProMetic Life Sciences Inc. - Immuron Limited - Phenex Pharmaceuticals AG - Wellstat Therapeutics Corporation - Zafgen Inc. - Conatus Pharmaceuticals Inc. - Intercept Pharmaceuticals, Inc. - Obio Pharmaceutical Holdings Limited - Tobira Therapeutics, Inc. - Jenken Biosciences, Inc - Kyorin Pharmaceutical Co., Ltd. - NasVax Ltd. - Stelic Institute & Co. - Galmed International Ltd. - Connexios Life Sciences Pvt. Ltd. - Kadmon Pharmaceuticals, LLC Drug Profiles - GFT-505 - KD-025 - obeticholic acid - liraglutide - Aramchol - emricasan - atorvastatin calcium - Anti-CD3 Oral Immunotherapy - IMM-124E - Px-102 - icosapent ethyl - BLX-1002 - tranilast - Px-104 - tipelukast - GR-MD-02 - GCS-100 - cenicriviroc - PN-2XXX - JKB-121 - JKB-119 - AK-20 - PBI-4050 - CNXFC-010 - ISIS-DGAT2Rx - ZGN-839 - remogliflozin etabonate - Small Molecule to Inhibit SCD-1 for NASH - Px-103 - STNM-09 For more information visit http://www.researchandmarkets.com/research/7d...nalcoholic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Commit To Purchase Intercept Pharmaceuticals At $150, Earn 28.7% Using Options
at The Street - Fri Apr 25, 10:43AM CDT
Investors eyeing a purchase of Intercept Pharmaceuticals Inc stock, but cautious about paying the going market price of $260.33/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put...
Stock Price Movements, Updates on Clinical Studies, Financial Results Releases, and Company Response to New Laws - Analyst Notes on Perrigo, GlaxoSmithKline, Intercept, Centene and Lorillard
PR Newswire - Fri Apr 25, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Perrigo Co. (NYSE: PRGO), GlaxoSmithKline plc (NYSE: GSK), Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), Centene Corp. (NYSE: CNC) and Lorillard, Inc. (NYSE: LO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1616-100free.
Today's Dead Cat Bounce Stock Is Intercept Pharmaceuticals (ICPT)
at The Street - Thu Apr 24, 9:43AM CDT
Trade-Ideas LLC identified Intercept Pharmaceuticals (ICPT) as a "dead cat bounce" (down big yesterday but up big today) candidate
Here's What This $69 Billion Pension Fund Has Been Buying
Selena Maranjian, The Motley Fool - Motley Fool - Wed Apr 23, 3:45PM CDT
Every quarter, many money managers have to disclose what they've bought and sold via 13F filings. Their latest moves can shine a bright light on smart stock picks. Today let's look at the California Public Employees Retirement System (often...
Nasdaq stocks posting largest percentage decreases
AP - Wed Apr 23, 12:37PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
The Biggest Biotech Wins of the Week
Cory Renauer, The Motley Fool - Motley Fool - Mon Apr 21, 5:30PM CDT
The iShares Nasdaq Biotechnology Index finally put up some gains last week as some big names released great news. It looks like GlaxoSmithKline might have an oral psoriasis candidate. Hemophilia giant Baxter might be adding another therapy to...
Earnings Results, Agreements, Study Results, FDA Approvals, and Drug Trial Results - Analyst Notes on Merck, Johnson & Johnson, GlaxoSmithKline, Novartis and Intercept
PR Newswire - Mon May 12, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Merck & Co. Inc. (NYSE: MRK), Johnson & Johnson (NYSE: JNJ), GlaxoSmithKline plc (NYSE: GSK), Novartis AG (NYSE: NVS) and Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2305-100free.
Why Tesla Motors, Dendreon, and Intercept Pharmaceuticals Tumbled Today
Dan Caplinger, The Motley Fool - Motley Fool - Thu May 08, 7:35PM CDT
The stock market nixed hopes that it would rise to unprecedented highs on Thursday, but investors still fared relatively well, with the major market benchmarks delivering mixed results after giving up much larger gains earlier in the day. Yet certain...
Diabetic Nephropathy - Pipeline Review, H1 2014: 37 Companies and 58 Drugs Profiled
M2 - Thu May 08, 3:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/x6n63h/diabetic) has announced the addition of the "Diabetic Nephropathy - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Nephropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Nephropathy and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Diabetic Nephropathy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Diabetic Nephropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved: - AbbVie Inc. - Ampio Pharmaceuticals, Inc. - Angelini Group - Astellas Pharma Inc. - Bayer AG - CCRP Therapeutics GmbH - ChemoCentryx, Inc. - Chong Kun Dang Pharmaceutical Corp. - Concert Pharmaceuticals, Inc. - Cyano Biotech GmbH - Daiichi Sankyo Company, Limited - Dongwha Pharm Co., Ltd. - Eli Lilly and Company - Emergent BioSolutions Inc. - Fibrotech Therapeutics Pty. Ltd. - GNI Group Ltd. - Galectin Therapeutics - GenKyoTex S.A. - Gentium S.p.A. - Glucox Biotech AB - IMMD Inc. - Intercept Pharmaceuticals, Inc. - Inventiva SAS - Johnson & Johnson - Mesoblast Limited - Mitsubishi Pharmaceutical Corporation - Mitsubishi Tanabe Pharma Corporation - NephroGenex, Inc. - Noxxon Pharma AG Drug Profiles: - canagliflozin - atrasentan hydrochloride - baricitinib - NOX-E-36 - IMD-1041 - CS-3150 - DW-1029M - GKT-137831 - PF-00489791 - CCX-140 - LY-2382770 - bindarit - Colchicine - probucol - PF-04634817 - Pyridoxamine Dihydrochloride - GLY-230 - corticotropin - CTP-499 - MT-3995 - finerenone - cilostazol - PHN-033 - CKD-322 - Allogeneic Mesenchymal Precursor Cells For Diabetic Nephropathy - LY-3016859 - FT-011 - ASP-8232 - pirfenidone - THR-123 For more information visit http://www.researchandmarkets.com/research/x6n63h/diabetic
Intercept Pharmaceuticals Reports First Quarter 2014 Financial Results
GlobeNewswire - Wed May 07, 3:47PM CDT
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) and nonalcoholic steatohepatitis (NASH), today reported financial results for the first quarter of 2014 and provided other general business updates. Intercept will hold a conference call and audio webcast today at 4:30 p.m. ET to review this information with conference call details provided below.
Kidney Fibrosis - Pipeline Review, H1 2014: 15 Company and 18 Drug Profiles
M2 - Wed May 07, 9:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6wq329/kidney_fibrosis) has announced the addition of the "Kidney Fibrosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Kidney Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Fibrosis and special features on late-stage and discontinued projects. This report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved: - AbbVie Inc. - Angion Biomedica Corp. - BiOrion Technologies B.V. - BioLineRx, Ltd. - CisThera Inc. - Compugen Ltd. - GNI Group Ltd. - Galectin Therapeutics - Galecto Biotech AB - Genzyme Corporation - Intercept Pharmaceuticals, Inc. - Paloma Pharmaceuticals, Inc. - ProMetic Life Sciences Inc. - Raptor Pharmaceuticals Corp. - Regulus Therapeutics Inc. Drug Profiles: - paricalcitol - F-351 - CGEN-856 - CGEN-857 - cysteamine DR - INT-767 - PBI-4050 - GR-MD-02 - Anti microRNA-21 - Galectin-3 Inhibitors - 1D-11 - CT-140 - BOT-191 - BOT-190 - SOL-1 - LJ-1888 - P-529 - ANG-3298 For more information visit http://www.researchandmarkets.com/research/6w...y_fibrosis
Intercept Reports Additional Positive OCA Data in Patients With Bile Acid Diarrhea at Digestive Disease Week
GlobeNewswire - Tue May 06, 3:24PM CDT
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept) today announced new OBADIAH trial results showing potential clinical benefits of obeticholic acid (OCA) for patients with bile acid diarrhea. OCA, Intercept's lead product candidate, is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR) in development for primary biliary cirrhosis (PBC), nonalcoholic steatohepatitis (NASH) and other liver and intestinal diseases, including bile acid diarrhea. The new OBADIAH trial results were presented today at Digestive Disease Week 2014 (DDW) in Chicago. OBADIAH is an investigator-initiated and sponsored open label Phase 2 trial conducted by Professor Julian Walters and colleagues at Imperial College, London in the United Kingdom. The trial evaluated once daily administration of 25 mg OCA for two weeks in 32 patients with diarrhea. Initial results from the OBADIAH trial in primary bile acid diarrhea were presented in 2013.
Intercept to Host First Quarter 2014 Update on May 7 and Present at Upcoming Investor Conferences
GlobeNewswire - Thu May 01, 5:05AM CDT
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver and intestinal diseases, today announced that it will report first quarter 2014 financial results after the NASDAQ Market closes on Wednesday, May 7, 2014. Intercept management will conduct a conference call and audio webcast on May 7, 2014 at 4:30 p.m. ET to discuss these results and provide an update on the company's business.
Intercept Pharmaceuticals Appoints Rachel McMinn, Ph.D. as Chief Strategy Officer
GlobeNewswire - Wed Apr 30, 3:49PM CDT
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver and intestinal diseases, today announced the appointment of Rachel McMinn, Ph.D. to the newly created position of Chief Strategy Officer.
Intercept Pharmaceuticals: What Investors Need to Watch
Brian Nichols, The Motley Fool - Motley Fool - Tue Apr 29, 5:30PM CDT
After soaring on positive clinical trial news in January, shares of Intercept Pharmaceuticals have fallen 50% from their highs. The biotech, which currently sports a market cap of $5.5 billion, jumped following positive data from its drug...
Global Diarrhea Therapeutics Pipeline Review 2014
M2 - Tue Apr 29, 8:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/63vt65/diarrhea) has announced the addition of the "Diarrhea - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Diarrhea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diarrhea and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Diarrhea - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Diarrhea and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Diarrhea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Diarrhea pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Ipsen S.A. - A. Menarini Industrie Farmaceutiche Riunite Srl - Shire Plc - Mucosis B.V. - Helsinn Healthcare S.A. - Ventria Bioscience - Ache Laboratorios Farmaceuticos S/A - Ocera Therapeutics, Inc. - GP Pharm, S.A. - Tioga Pharmaceuticals, Inc. - Intercept Pharmaceuticals, Inc. - Aegis Therapeutics, LLC - Drais Pharmaceuticals, Inc. - DesignMedix, Inc. - Chongqing Zhifei Biological Products Co., Ltd. - Rottapharm|Madaus - Sanofi Pasteur SA - Inhibikase Therapeutics, Inc. - Rebiotix Inc. For more information visit http://www.researchandmarkets.com/research/63vt65/diarrhea
Global Non-Alcoholic Steatohepatitis Therapeutics Pipeline Review 2014 - Analysis of 24 Companies & 31 Drug Profiles
M2 - Mon Apr 28, 5:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7dwrzr/nonalcoholic) has announced the addition of the "Non-Alcoholic Steatohepatitis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Non-Alcoholic Steatohepatitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Non-Alcoholic Steatohepatitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Non-Alcoholic Steatohepatitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Non-Alcoholic Steatohepatitis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Isis Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Novo Nordisk A/S - Mochida Pharmaceutical Co., Ltd. - Kissei Pharmaceutical Co., Ltd. - Genfit SA - Orchid Chemicals & Pharmaceuticals Ltd - La Jolla Pharmaceutical Company - ProMetic Life Sciences Inc. - Immuron Limited - Phenex Pharmaceuticals AG - Wellstat Therapeutics Corporation - Zafgen Inc. - Conatus Pharmaceuticals Inc. - Intercept Pharmaceuticals, Inc. - Obio Pharmaceutical Holdings Limited - Tobira Therapeutics, Inc. - Jenken Biosciences, Inc - Kyorin Pharmaceutical Co., Ltd. - NasVax Ltd. - Stelic Institute & Co. - Galmed International Ltd. - Connexios Life Sciences Pvt. Ltd. - Kadmon Pharmaceuticals, LLC Drug Profiles - GFT-505 - KD-025 - obeticholic acid - liraglutide - Aramchol - emricasan - atorvastatin calcium - Anti-CD3 Oral Immunotherapy - IMM-124E - Px-102 - icosapent ethyl - BLX-1002 - tranilast - Px-104 - tipelukast - GR-MD-02 - GCS-100 - cenicriviroc - PN-2XXX - JKB-121 - JKB-119 - AK-20 - PBI-4050 - CNXFC-010 - ISIS-DGAT2Rx - ZGN-839 - remogliflozin etabonate - Small Molecule to Inhibit SCD-1 for NASH - Px-103 - STNM-09 For more information visit http://www.researchandmarkets.com/research/7d...nalcoholic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Commit To Purchase Intercept Pharmaceuticals At $150, Earn 28.7% Using Options
at The Street - Fri Apr 25, 10:43AM CDT
Investors eyeing a purchase of Intercept Pharmaceuticals Inc stock, but cautious about paying the going market price of $260.33/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put...
Stock Price Movements, Updates on Clinical Studies, Financial Results Releases, and Company Response to New Laws - Analyst Notes on Perrigo, GlaxoSmithKline, Intercept, Centene and Lorillard
PR Newswire - Fri Apr 25, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Perrigo Co. (NYSE: PRGO), GlaxoSmithKline plc (NYSE: GSK), Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), Centene Corp. (NYSE: CNC) and Lorillard, Inc. (NYSE: LO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1616-100free.
Today's Dead Cat Bounce Stock Is Intercept Pharmaceuticals (ICPT)
at The Street - Thu Apr 24, 9:43AM CDT
Trade-Ideas LLC identified Intercept Pharmaceuticals (ICPT) as a "dead cat bounce" (down big yesterday but up big today) candidate
Here's What This $69 Billion Pension Fund Has Been Buying
Selena Maranjian, The Motley Fool - Motley Fool - Wed Apr 23, 3:45PM CDT
Every quarter, many money managers have to disclose what they've bought and sold via 13F filings. Their latest moves can shine a bright light on smart stock picks. Today let's look at the California Public Employees Retirement System (often...
Nasdaq stocks posting largest percentage decreases
AP - Wed Apr 23, 12:37PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
The Biggest Biotech Wins of the Week
Cory Renauer, The Motley Fool - Motley Fool - Mon Apr 21, 5:30PM CDT
The iShares Nasdaq Biotechnology Index finally put up some gains last week as some big names released great news. It looks like GlaxoSmithKline might have an oral psoriasis candidate. Hemophilia giant Baxter might be adding another therapy to...
